Reproducibility of Flow Cytometry Through Standardization: Opportunities and Challenges
暂无分享,去创建一个
[1] J. Reilly,et al. UK NEQAS for leucocyte immunophenotyping: the first 10 years , 2001, Journal of clinical pathology.
[2] S. Baumgart,et al. OMIP‐034: Comprehensive immune phenotyping of human peripheral leukocytes by mass cytometry for monitoring immunomodulatory therapies , 2017, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[3] Heavy metal contaminants can eliminate quantum dot fluorescence , 2011, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[4] Raphael Gottardo,et al. flowCL: ontology-based cell population labelling in flow cytometry , 2015, Bioinform..
[5] B. Sawitzki,et al. Standardized Multi-Color Flow Cytometry and Computational Biomarker Discovery. , 2016, Methods in molecular biology.
[6] D. Barnett,et al. Laboratory Accuracy Improvement in the UK NEQAS Leucocyte Immunophenotyping Immune Monitoring Program: An Eleven‐Year Review via Longitudinal Mixed Effects Modeling , 2018, Cytometry. Part B, Clinical cytometry.
[7] M. Roederer. How many events is enough? Are you positive? , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[8] A Orfao,et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma , 2017, Leukemia.
[9] A. Porwit,et al. Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part III – analytical issues , 2013, Cytometry. Part B, Clinical cytometry.
[10] A Orfao,et al. EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine , 2012, Leukemia.
[11] M. van der Burg,et al. Optimization and testing of dried antibody tube: The EuroFlow LST and PIDOT tubes as examples. , 2017, Journal of immunological methods.
[12] E. Montserrat,et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL , 2013, Leukemia.
[13] Shannon McWeeney,et al. MIFlowCyt: The minimum information about a flow cytometry experiment , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[14] Alberto Orfao,et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. , 2015, Blood.
[15] J. Reilly,et al. Quality control of CD4+ T-lymphocyte enumeration: results from the last 9 years of the United Kingdom National External Quality Assessment Scheme for Immune Monitoring (1993-2001). , 2002, Cytometry.
[16] R. Nussenblatt,et al. Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[17] H. Maecker,et al. Selecting fluorochrome conjugates for maximum sensitivity , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[18] Elena Blanco,et al. The EuroFlow PID Orientation Tube for Flow Cytometric Diagnostic Screening of Primary Immunodeficiencies of the Lymphoid System , 2019, Front. Immunol..
[19] Bertil Magnusson,et al. Understanding the meaning of accuracy, trueness and precision , 2007 .
[20] M. Keeney,et al. Novel lymphocyte screening tube using dried monoclonal antibody reagents , 2015, Cytometry. Part B, Clinical cytometry.
[21] M. van der Burg,et al. Defects in memory B-cell and plasma cell subsets expressing different immunoglobulin-subclasses in patients with CVID and immunoglobulin subclass deficiencies. , 2019, The Journal of allergy and clinical immunology.
[22] Jaebok Choi,et al. OMIP‐042: 21‐color flow cytometry to comprehensively immunophenotype major lymphocyte and myeloid subsets in human peripheral blood , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[23] V. Appay,et al. Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[24] N. Packer,et al. Specific Sialoforms Required for the Immune Suppressive Activity of Human Soluble CD52 , 2019, Front. Immunol..
[25] R. Arceci,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study , 2009 .
[26] Tomáš Kalina,et al. How to make usage of the standardized EuroFlow 8-color protocols possible for instruments of different manufacturers. , 2017, Journal of immunological methods.
[27] F Lacombe,et al. Harmonemia: a universal strategy for flow cytometry immunophenotyping—A European LeukemiaNet WP10 study , 2016, Leukemia.
[28] Ming Yan,et al. Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part V – assay performance criteria , 2013, Cytometry. Part B, Clinical cytometry.
[29] M. Loh,et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.
[30] Andreas Grützkau,et al. Stabilizing Antibody Cocktails for Mass Cytometry , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[31] T. Kalina,et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols , 2012, Leukemia.
[32] E. Huys,et al. Establishment of harmonization in immunophenotyping: A comparative study of a standardized one-tube lymphocyte-screening panel. , 2014, Cytometry. Part B, Clinical cytometry.
[33] T. Eckschlager. [CD nomenclature]. , 2003, Vnitrni lekarstvi.
[34] Hannes Stockinger,et al. CD Nomenclature 2015: Human Leukocyte Differentiation Antigen Workshops as a Driving Force in Immunology , 2015, The Journal of Immunology.
[35] T. Kalina,et al. Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping , 2014, Cytometry. Part B, Clinical cytometry.
[36] Teri Oldaker,et al. Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part I – rationale and aims , 2013, Cytometry. Part B, Clinical cytometry.
[37] N. Aghaeepour,et al. Thinking outside the gate: single-cell assessments in multiple dimensions. , 2015, Immunity.
[38] Mario Roederer,et al. OMIPs—Orchestrating multiplexity in polychromatic science , 2010, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[39] Hana Glier,et al. Standardization of 8-color flow cytometry across different flow cytometer instruments: A feasibility study in clinical laboratories in Switzerland. , 2017, Journal of immunological methods.
[40] F. Rieux-Laucat,et al. Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.
[41] M. van der Burg,et al. Age‐associated distribution of normal B‐cell and plasma cell subsets in peripheral blood , 2018, The Journal of allergy and clinical immunology.
[42] Lili Wang,et al. Methodology for evaluating and comparing flow cytometers: A multisite study of 23 instruments , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[43] T. Kalina,et al. Frequent issues and lessons learned from EuroFlow QA. , 2018, Journal of immunological methods.
[44] H. Maecker,et al. A Model for Harmonizing Flow Cytometry in Clinical Trials , 2022 .
[45] Carlos Eduardo Pedreira,et al. A Multidimensional Classification Approach for the Automated Analysis of Flow Cytometry Data , 2008, IEEE Transactions on Biomedical Engineering.
[46] F. Lacombe,et al. Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[47] M. van der Burg,et al. Selection and validation of antibody clones against IgG and IgA subclasses in switched memory B-cells and plasma cells. , 2019, JIM - Journal of Immunological Methods.
[48] Quentin Lecrevisse,et al. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia. , 2017, Blood.
[49] I. Storie,et al. Absolute CD4+ T‐lymphocyte and CD34+ stem cell counts by single‐platform flow cytometry: the way forward , 1999, British journal of haematology.
[50] M. Jaimes,et al. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI) , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[51] A Orfao,et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes , 2012, Leukemia.
[52] J. P. McCoy,et al. Standardizing Flow Cytometry Immunophenotyping Analysis from the Human ImmunoPhenotyping Consortium , 2016, Scientific Reports.
[53] J. Paul Robinson,et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. , 2017, European journal of immunology.
[54] Holden T. Maecker,et al. Erratum: Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[55] James A. Hutchinson,et al. Age and gender leucocytes variances and references values generated using the standardized ONE‐Study protocol , 2016, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[56] J. Reilly,et al. ISHAGE protocol: Are we doing it correctly? , 2012, Cytometry. Part B, Clinical cytometry.
[57] S. Papa,et al. Reduction of intra‐ and interlaboratory variation in CD34+ stem cell enumeration using stable test material, standard protocols and targeted training , 2000, British journal of haematology.
[58] Jin-Yeong Han,et al. Validation of cell‐based fluorescence assays: practice guidelines from the ICSH and ICCS – part II – preanalytical issues , 2013, Cytometry. Part B, Clinical cytometry.
[59] R. Emerson,et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study , 2015, Leukemia.
[60] W. V. van Wieringen,et al. Flow cytometric CD34+ stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries , 2007, Cytometry. Part B, Clinical cytometry.
[61] F. Durrieu,et al. Acceptable “Real‐Life” Variability for Lymphocyte Counts by Flow Cytometry , 2018, Cytometry. Part B, Clinical cytometry.
[62] Antonio Cosma,et al. Universal cell type identifier based on number theory , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[63] T. Kalina,et al. Common Variable Immunodeficiency patients with a phenotypic profile of immunosenescence present with thrombocytopenia , 2017, Scientific Reports.
[64] Barbara Buldini,et al. AIEOP‐BFM Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia , 2018, Cytometry. Part B, Clinical cytometry.
[65] Raphael Gottardo,et al. Computational resources for high-dimensional immune analysis from the Human Immunology Project Consortium , 2014, Nature Biotechnology.
[66] F. Preffer,et al. Flow cytometry and the stability of phycoerythrin‐tandem dye conjugates , 2009, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[67] D. Barnett,et al. Validation of cell‐based fluorescence assays: Practice guidelines from the ICSH and ICCS – part IV – postanalytic considerations , 2013, Cytometry. Part B, Clinical cytometry.
[68] Florian Mair,et al. OMIP‐044: 28‐color immunophenotyping of the human dendritic cell compartment , 2018, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[69] V. Maino,et al. Standardization and optimization of multiparameter intracellular cytokine staining , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[70] J Verde,et al. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia , 2017, Leukemia.
[71] Kirsten E Diggins,et al. Generating Quantitative Cell Identity Labels with Marker Enrichment Modeling (MEM) , 2018, Current protocols in cytometry.
[72] C. Meisel,et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study , 2013, Transplantation research.
[73] R. Hoffman,et al. Determination of CD4 antigen density on cells: role of antibody valency, avidity, clones, and conjugation. , 1998, Cytometry.
[74] F. Preijers,et al. Establishment of harmonization in immunophenotyping: A comparative study of a standardized one‐tube lymphocyte‐screening panel , 2014 .
[75] Kenneth D Cole,et al. Human CD4+ lymphocytes for antigen quantification: Characterization using conventional flow cytometry and mass cytometry , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[76] C. E. Pedreira,et al. Quality assessment program for EuroFlow protocols: Summary results of four‐year (2010–2013) quality assurance rounds , 2015, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[77] Barbara Buldini,et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia , 2015, Haematologica.
[78] M. Roederer,et al. Optimizing a multicolor immunophenotyping assay. , 2007, Clinics in laboratory medicine.
[79] C. E. Pedreira,et al. Lot-to-lot stability of antibody reagents for flow cytometry. , 2017, Journal of immunological methods.
[80] M. van der Burg,et al. EuroFlow-Based Flowcytometric Diagnostic Screening and Classification of Primary Immunodeficiencies of the Lymphoid System , 2019, Front. Immunol..
[81] F. Sallusto,et al. The who's who of T‐cell differentiation: Human memory T‐cell subsets , 2013, European journal of immunology.
[82] Bruce Greig,et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia , 2007, Cytometry. Part B, Clinical cytometry.
[83] V. V. D. van der Velden,et al. Fifteen years of external quality assessment in leukemia/lymphoma immunophenotyping in The Netherlands and Belgium: A way forward , 2016, Cytometry. Part B, Clinical cytometry.
[84] Tomas Kalina,et al. Relevance of Antibody Validation for Flow Cytometry , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[85] Gary Kelloff,et al. A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters , 2018, Cytometry. Part B, Clinical cytometry.
[86] R. Brant,et al. A standardized immune phenotyping and automated data analysis platform for multicenter biomarker studies. , 2018, JCI insight.
[87] Giuseppe Basso,et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible , 2008, Cytometry. Part B, Clinical cytometry.
[88] J. Byrd,et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia , 2007, Leukemia.
[89] Christophe Jamin,et al. Multi-center harmonization of flow cytometers in the context of the European "PRECISESADS" project. , 2016, Autoimmunity reviews.